AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

The article favors AbbVie over Novo Nordisk for long-term investors, citing expectations that AbbVie’s sales will reach $67.2 billion and net income will rise from $4.2 billion to $14.6 billion this year. Novo Nordisk faces projected FY 2026 sales declines of about 3% and net income declines of 4%, despite the success of its Wegovy pill and a lower valuation (11.7x forward P/E vs. AbbVie’s 20.2x). The comparison highlights AbbVie’s growth pipeline and acquisition alongside risks for both companies, including pricing pressure, competition, and patent exposure.

Analysis

The key distinction is earnings durability, not which company has the lower multiple. NVO’s discount may already reflect a difficult 2026 reset; a low forward multiple is not a catalyst if net pricing, share, or mix keep moving against it. Conversely, any evidence that the oral formulation expands treated patients without cannibalizing higher-value supply could quickly challenge the “value trap” framing. Track prescription volumes, realized net price, and capacity utilization—not launch claims alone. LLY is the pivotal competitive read-through: stronger-than-expected share gains would pressure NVO’s pricing power and could reset category expectations.

ABBV offers a different risk: investors are underwriting replacement growth and pipeline execution after Humira, while the stated valuation leaves less room for disappointment. Skyrizi/Rinvoq concentration makes any uptake, safety, or payer-access miss consequential. The article’s projected jump in net income from $4.2B to $14.6B is not interpretable without confirming GAAP versus adjusted earnings and one-off items; do not capitalize it as recurring growth yet. Wholesaler concentration is a continuity and bargaining risk, but absent evidence of deteriorating terms it is not a standalone short thesis on MCK, CAH, or COR.

Near term, avoid treating this comparison as a clean “growth versus value” call. Over 1–3 months, earnings commentary on NVO net pricing/capacity and ABBV’s underlying adjusted growth should determine relative positioning. Over 6–18 months, NVO’s competitive and reimbursement trajectory is the larger downside tail; ABBV’s is pipeline conversion and concentrated-product execution. The contrarian risk is that NVO’s low multiple and negative sentiment make a modest supply or demand surprise a sharp upside catalyst, while ABBV’s upbeat narrative may already price in successful diversification.

Key Decisions for Investors

• No outright NVO short solely on valuation or the article’s forecasts. Keep it on watch; add exposure only if prescription growth and manufacturing availability improve without material net-price deterioration. Thesis weakens if LLY gains share while NVO lowers realized prices or trims outlook.
• For a relative-value expression, consider a modest long ABBV / short NVO pair only after reconciling ABBV’s cited earnings forecast to recurring, comparable GAAP or adjusted figures. Size conservatively: ABBV carries execution and concentration risk, while NVO can rebound sharply on supply or oral-product traction.
• Near-term catalyst checklist: ABBV adjusted earnings, Skyrizi/Rinvoq growth and payer access; NVO prescription volumes, realized pricing, capacity and guidance; and LLY competitive updates. Reassess the pair if either company materially changes guidance or if underlying product growth diverges from the thesis.